TVRD MEXC RealStocks
Own real TVRD shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 08:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tvardi Therapeutics, Inc. (TVRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.18, with a market capitalization of $15.41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.77 to $5.69. This page covers its latest market performance, valuation, price trends and company information.
$15.41M | |
$1.16 | |
$1.18 | |
$1.09 | |
$1.16 | |
73.00K | |
242.59K | |
-- | |
$5.69 | |
$0.77 | |
-- | |
-- |
Tvardi Therapeutics, Inc. (TVRD) last closed at $1.18 as of 2026-11-14 00:43:00, up 2.16% ($0.02) from the previous close of $1.16.
During the latest regular trading session, TVRD traded between $1.09 and $1.18, with a volume of 73.00K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Tvardi Therapeutics, Inc. (TVRD) moved from $0.86 to $1.18, representing a gain of 35.92% ($0.31).
The stock traded between $0.81 and $1.61 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 868.39 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.2%
TVRD is currently trading at $1.18, placing it 8.2% of the way from its 52-week low of $0.77 to its 52-week high of $5.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tvardi Therapeutics, Inc. (TVRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TVRD, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TVRD shares and USD.
TVRD Shares to USD
1.00 TVRD shares = 1.175 USD
Calculations are estimates based on the latest available price and are for reference only.